#alzheimer's biomarkers
Discover 3 curated intelligence briefings related to this specific topic.
The End of the Waiting Game: Blood-Based Biomarkers and the New Era of Predictive Neuro-Diagnostics
The medical community is witnessing a fundamental pivot in dementia care. We are moving from a reactive model—diagnosing decline after it manifests—to a predictive model using blood-based biomarkers that identify pathology decades before the first memory lapse.
The Mitochondrial Protocol: Engineering Cellular Energy for Peak Human Performance
Move beyond symptom management. This guide details the precise molecular frameworks for NAD+ restoration, ETC optimization, and the strategic management of the mTOR-autophagy pathway to rewrite your biological trajectory.
The Pre-Symptomatic Pivot: Why a Blood Test for Dementia is a Systemic Shock
The emergence of high-accuracy blood biomarkers like p-tau217 is shifting dementia diagnosis from a reactive event to a proactive surveillance model, creating a 20-year window of anticipation that challenges global healthcare infrastructures and the definition of patienthood.